Navigation Links
AstraZeneca Sued Over Alleged Nexium Injuries, According to The Gibson Law Firm
Date:4/19/2011

HOUSTON, April 19, 2011 /PRNewswire/ -- An Ohio woman suffered bone deterioration and broken bones because of hidden risks with pharmaceutical giant AstraZeneca's acid reflux drug Nexium, The Gibson Law Firm alleges in a lawsuit filed today in Texas federal court.

Filed in the U.S. District Court in Houston, the lawsuit alleges 58-year-old Ginny Begin, of Toledo, Ohio, suffered serious bone deterioration after taking Nexium on a daily basis between 2003 and early 2011.

In March, the FDA issued a safety alert stating use of prescription "PPI's," including Nexium, results in an increased risk of fractures. PPI's are prescription-strength proton pump inhibitors. In May 2010, the FDA mandated manufacturers of PPI's such as Nexium to include safety information and warnings about the increased risk of osteoporosis and fractures associated with PPIs.

The lawsuit alleges, "[A]s early as 2006, studies found PPI's, by reducing hydrochloric acid in the stomach, interfere with the body's ability to absorb calcium, thus speeding up bone loss and leading to an increased number of fractures. In total, six studies have found the risk of fracture significantly increased for those patients over 50 years of age who took a prescription-strength PPI, like Nexium, or who took any PPI regularly for more than one year. Specifically, use of PPI's increases the risk of fractures in women up to 34 percent."

According to the complaint, Begin snapped a leg bone (left fibula) in July 2005 while walking. In June 2007, the same bone in Begin's leg and three bones in her ankle broke as she walked down stairs.

Jason A. Gibson of The Gibson Law Firm in Houston represents Begin. He stated, "Despite knowing Nexium causes bones to severely deteriorate and break, AstraZeneca marketed and sold Nexium without warning consumers of the significant risks of bone deterioration and fractures. Ms. Begin continues to suffer severe pain from leg and ankle injuries that never fully healed. Our investigation of national impact on consumers who took Nexium continues. This appears to be the first known lawsuit filed against AstraZeneca arising from bone fractures caused by Nexium."

The lawsuit accuses AstraZeneca, L.P. and AstraZeneca Pharmaceuticals, L.P. of negligence, negligent misrepresentation and product defects, and seeks exemplary damages.

The case is "Ginny Begin v. AstraZeneca, L.P.," Civil Action No. 4:11-CV-01489 in the U.S. District Court for the Southern District of Texas, Houston Division.

www.jag-lawfirm.com.


'/>"/>
SOURCE The Gibson Law Firm
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
2. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
3. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
4. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
5. AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication
6. Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
7. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
8. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
9. AstraZeneca Submits sNDA for NEXIUM(R) I.V. for Peptic Ulcer Bleed Indication
10. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
11. AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016   Bay Area Lyme Foundation ... Dean Center for Tick Borne Illness , Harvard ... MIT Hacking Medicine, University of California, Berkeley, and ... the five finalists of Lyme Innovation , ... than 100 scientists, clinicians, researchers, entrepreneurs, and investors ...
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016  American Respiratory ... testing company, is now able to perform sophisticated lung assessments in ... Medical Technologies , Inc. Patients are no longer ... to ndd,s EasyOne PRO ® , ARL patients like Jeanne R. ... testing done in the comfort of her own home. ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, ... less invasive and more durable cerebrospinal fluid treatments, ... funding.  The Series-A funding is led by Innova ... Fund, and other private investors.  Arkis, new financing ... instrumentation and the market release of its in-licensed ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the ... as Vice President of North American Capital Sales at HTG Molecular . ... team in the commercialization of the HTG EdgeSeq system and associated reagents in North ...
Breaking Medicine News(10 mins):